Provided by Tiger Trade Technology Pte. Ltd.

Monopar Therapeutics

109.60
-2.2900-2.05%
Volume:76.42K
Turnover:8.37M
Market Cap:732.41M
PE:-50.27
High:111.99
Open:110.70
Low:106.76
Close:111.89
52wk High:124.82
52wk Low:32.77
Shares:6.68M
Float Shares:4.48M
Volume Ratio:0.91
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1804
EPS(LYR):-1.8509
ROE:-19.50%
ROA:-14.64%
PB:5.60
PE(LYR):-59.22

Loading ...

Monopar Initiates Rolling Nda Submission for Alxn1840 in Wilson Disease

THOMSON REUTERS
·
Jul 22

Monopar Adds Ex-kalvista CCO Nicole Sweeny to Board

Reuters
·
Jul 20

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

THOMSON REUTERS
·
Jul 20

Monopar Therapeutics price target raised to $117 from $104 at BTIG

TIPRANKS
·
Jul 01

Monopar Therapeutics Director Nicole Sweeny Files Initial Beneficial Ownership Statement

Reuters
·
Jul 01

Monopar Says FDA Grants Rare Pediatric Disease Designation for Alxn1840 in Wilson Disease

Reuters
·
Jun 30

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for Alxn1840 for the Treatment of Wilson Disease

THOMSON REUTERS
·
Jun 30

Monopar Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Jun 30

Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Jun 29

Monopar Therapeutics Price Target Maintained with a $105.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Monopar Therapeutics Inc (MNPR) and Bio-Techne (TECH)

TIPRANKS
·
Jun 29

Monopar Therapeutics announces new FoCus trial analyses

TIPRANKS
·
Jun 27

Monopar Says Phase 3 Focus Analysis Shows Alxn1840 Outperforms Standard Care in Neurologic Wilson Disease Patients

Reuters
·
Jun 27

Monopar Therapeutics holds annual shareholder meeting

Reuters
·
Jun 23

Monopar Therapeutics management to meet virtually with Piper Sandler

TIPRANKS
·
Jun 23

Monopar Therapeutics Inc (MNPR) Receives a Buy from Piper Sandler

TIPRANKS
·
Jun 02

Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Gossamer Bio (GOSS)

TIPRANKS
·
Jun 01

Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Jun 01

Monopar presents Phase 2 data showing ALXN1840 stabilizes liver disease in Wilson patients at EASL 2026

Reuters
·
Jun 01

Monopar says Phase 2 trial shows ALXN1840 improves copper balance in Wilson disease

Reuters
·
May 20